预约演示

更新于：2025-08-14

Diclofenac Sodium

双氯芬酸钠

更新于：2025-08-14

概要

基本信息

简介双氯酚酸钠是苯乙酸衍生物，是一种非甾体抗炎药（NSAID），具有镇痛、抗炎和解热作用。和其他NSAIDs一样，双氯酚酸钠的作用机制尚未完全理解，但涉及抑制环氧化酶（COX-1和COX-2）。FDA于1988年7月28日批准双氯酚酸钠（VOLTAREN ）上市，其原产公司为Ciba-Geigy公司，现已并入诺华。这种药物已经长期用于管理多种疼痛症状，并且有处方和非处方制剂

药物类型

小分子化药

别名

Diclfenac Sodium、Diclofanac Sodium、DICLOFENAC

+ [119]

靶点

COXs

作用方式

抑制剂

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

免疫系统疾病神经系统疾病皮肤和肌肉骨骼疾病+ [5]

在研适应症

滑囊炎颈臂综合征腰痛+ [23]

非在研适应症

光化性角化病晚期恶性实体瘤踝损伤+ [12]

原研机构

Novartis Pharma AG

在研机构

江苏思邈医药科技有限公司

百时益医药研发（北京）有限公司

Hisamitsu Pharmaceutical Co., Inc.

+ [10]

非在研机构

Novartis AGJAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUDSIDIARY OF HOSPIRA INC

Fougera Pharmaceuticals, Inc.

+ [7]

权益机构

Dr. Reddy's Laboratories Ltd.

Mundipharma International Ltd.

Sayre Therapeutics Pvt Ltd.

+ [9]

最高研发阶段批准上市

首次获批日期

日本 (1973-08-08),

炎症疼痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H11Cl2NNaO2

InChIKeyVSFBPYWDRANDLM-UHFFFAOYSA-N

CAS号15307-79-6

关联

622

项与双氯芬酸钠相关的临床试验

NCT03595150

/ Not yet recruiting临床2/3期IIT

Diclofenac for Prevention of Post-ERC Pancreatitis

The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.

开始日期2026-01-01

申办/合作机构

Karolinska Institutet

[+1]

NCT06207253

/ Recruiting临床2/3期IIT

The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament During Root Canal Treatment: A Randomized Clinical Trial

The goal of this randomized clinical trial is to evaluate the capability of the material to exert bacterial reduction of diclofenac sodium versus of that calcium hydroxide paste when these materials are used as intracanal medications in permanent molar teeth with chronic apical periodontitis.
The main question[s] it aims to answer are:
• Will the diclofenac sodium (NSAIDs) possess antimicrobial efficacy to be used effectively as an intracanal medicament similar to that of calcium hydroxide in primary endodontic treatment? Participants will be allocated randomly into three equal groups by using computer generated randomization, according to the type of intracanal medication.

开始日期2025-11-01

申办/合作机构

British University of Egypt

NCT07079969

/ Not yet recruiting临床2期IIT

Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis

This study aims to compare the effects of combined treatments-dual-wavelength photobiomodulation (PBM) with or without topical diclofenac-on inflammation, pain, and joint function in patients with knee osteoarthritis (OA). It also seeks to determine the synergistic effect of PBM plus topical diclofenac on inflammatory markers, pain scores, and functional outcomes.

开始日期2025-08-01

申办/合作机构

University of Florida

100 项与双氯芬酸钠相关的临床结果

登录后查看更多信息

100 项与双氯芬酸钠相关的转化医学

登录后查看更多信息

100 项与双氯芬酸钠相关的专利（医药）

登录后查看更多信息

19,463

项与双氯芬酸钠相关的文献（医药）

2025-12-01·Water Research X

Micropollutants removal, residual risk, and costs for quaternary treatments in the framework of the Urban Wastewater Treatment Directive

作者: Antonelli, Manuela ; Piraldi, Sara ; Ianes, Jessica ; Cantoni, Beatrice

The revised Urban Wastewater Treatment Directive (UWWTD) imposes stringent regulations for the removal of micropollutants from urban wastewater treatment plants.The analyses conducted in this study are based on current knowledge extrapolated from literature WWTPs, to investigate the occurrence, removal and environmental risk related to the 12 target micropollutants: Amisulpride, Benzotriazole, 4,5-Methylbenzotriazole, Carbamazepine, Clarithromycin, Citalopram, Candesartan, Diclofenac, Hydrochlorothiazide, Irbesartan, Metoprolol, and Venlafaxine.The goal is to provide valuable insights into the challenges and opportunities associated with implementing quaternary treatment processes to comply with the UWWTD.It indicate that the conventional biol. treatment is insufficient, with median removal rates below 50% for most target micropollutants (except for Benzotriazole and Irbesartan).The implementation of quaternary treatment processes, namely ozonation and activated carbon adsorption, significantly enhances WWTP micropollutants removal, with median removal efficiencies exceeding 80% for all the target micropollutants, with Candesartan being the most recalcitrant.Environmental risk assessment reveals that some micropollutants pose a significant threat to aquatic ecosystems even with 80% removal efficiency (Irbesartan, Candesartan, Diclofenac, and Venlafaxine), while others do not pose a risk even at WWTP influent concentrations (4,5-Methylbenzotriazole, Hydrochlorothiazide, Amisulpride, Citalopram, and Metoprolol).Economic anal. shows that the selection of specific operating parameter values significantly impacts the cost of each treatment process, changing the economic feasibility ranking of the different treatment options.

2025-11-01·APPLIED CATALYSIS B-ENVIRONMENTAL

Identification of reactive species and functional groups determining the selective oxidation of organic contaminants in Bismuth ferrate/peroxymonosulfate system

作者: Shao, Dan ; Zhang, Yuanyuan ; Rao, Yongfang ; Yan, Wei ; Cui, Jiahao ; Cui, Miaoying

The reactive species and functional groups determining the major reactive species contributing to the degradation of organic pollutants were identified in the Bi₂Fe₄O₉/PMS (BFO/PMS) system.Competitive degradation, radical quenching experiments of organic contaminants, PMSO₂ generation, Raman spectroscopy, ¹⁸O isotope labeling experiments and the comparison of sulfadiazine degradation intermediates suggest the generation of both free radical and high-valent iron in BFO/PMS system.The groups determining the high-valent iron oxidation pathways for different organic contaminants were identified resp. (acetaminophen: -OH, sulfadiazine: -NH₂, diclofenac: -NH-, ciprofloxacin: -NH- and N-R3).The linear relationship between Hammett′s constants and the contribution of high-valent iron oxidation to the degradation of homologues under neutral condition was established.This study provides a novel insight into heterogeneous activation mechanisms of PMS and helps predict the fate of various organic pollutants carrying different functional groups during environmental remediation by the activation of PMS by iron-based catalysts.

2025-11-01·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

Effect of microplastics on the photodegradation of high-consumption drugs under simulated sunlight: The critical role of aging and reactive oxygen species

作者: Kalaronis, Dimitrios ; Kyzas, George Z. ; Bikiaris, Dimitrios N. ; Evgenidou, Eleni ; Lambropoulou, Dimitra A. ; Teknetzi, Aikaterini ; Vourlias, George

The main aim of this study was to examine the effect of polypropylene (PP), poly(ethylene terephthalate) (PET), and poly(lactic acid) (PLA) microplastics (MPs) on the photolytic degradation of a mixture of seven commonly used pharmaceuticals under simulated solar irradiation (SSL).The target mixture included four common antibiotics (metronidazole, trimethoprim, indomethacin, isoniazid), two non-steroidal anti-inflammatory drugs (diclofenac, ketoprofen), and one antihypertensive drug (valsartan).The selected MPs were aged using three different procedures: (i) SSL light, (ii) UV/H₂O₂, and (iii) Fenton reagent.The effect of MPs mass concentration was examined using only the pristine MPs, while the aging effect was evaluated for the three different aged MPs for each polymer type.The results demonstrated that the presence of MPs generally accelerates the photolytic degradation of the drugs, and increasing their concentration further enhances the reaction rate.Aging of the MPs also appeared to enhance the photodegradation of the selected pharmaceuticals.Among the various aging processes applied, UV/H2O2 had the greatest impact on surface alteration of the MPs and consequently, UV/H₂O₂-aged PET MPs exhibited the highest influence on the photolytic degradation of the drugs.To gain a deeper understanding of the mechanism behind the photolytic degradation of the examined pharmaceuticals, a systematic characterization of pristine and aged MPs was conducted using Fourier transformed IR spectroscopy (FTIR), XPS, and SEM-energy dispersive X-ray spectroscopy (SEM-EDX) techniques, which detected the formation of oxygen containing groups on the MPs' surfaces.Finally, scavenger experiments were also conducted to explore the formation and role of reactive oxygen species (singlet oxygen, superoxide anions, and hydroxyl radicals) in the degradation of the target compounds

216

项与双氯芬酸钠相关的新闻（医药）

2025-08-10

·信狐药迅

石药集团司美格鲁肽和君实生物特瑞普利单抗提交2.2类新适应症上市申请|新受理（8.4-8.10）

本周药品注册受理数据，分门别类呈现，一目了然。(8.4-8.10）新药上市申请药品名称企业注册分类受理号司美格鲁肽注射液石药集团百克(山东)生物制药股份有限公司2.2CXHS2500090司美格鲁肽注射液石药集团百克(山东)生物制药股份有限公司2.2CXHS2500091特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS2500080特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS2500079 新药临床申请药品名称企业注册分类受理号HRS-7058片山东盛迪医药有限公司1CXHL2500832HRS-7058片山东盛迪医药有限公司1CXHL2500831HRS-7058胶囊山东盛迪医药有限公司1CXHL2500830HRS-7058胶囊山东盛迪医药有限公司1CXHL2500829HRS-4642注射液上海恒瑞医药有限公司1CXHL2500827HRS-4642注射液上海恒瑞医药有限公司1CXHL2500826TQB3122胶囊正大天晴药业集团股份有限公司1CXHL2500825TQB3122胶囊正大天晴药业集团股份有限公司1CXHL2500824HRS-4642注射液上海恒瑞医药有限公司1CXHL2500821HRS-4642注射液上海恒瑞医药有限公司1CXHL2500820注射用TQB3142正大天晴药业集团股份有限公司1CXHL2500819HECN30227注射液广东东阳光药业股份有限公司1CXHL2500818ZN-F-6418胶囊苏州赞荣医药科技有限公司1CXHL2500817ZN-F-6418胶囊苏州赞荣医药科技有限公司1CXHL2500816IPG7236片南京艾美斐生物医药科技有限公司1CXHL2500814IPG7236片南京艾美斐生物医药科技有限公司1CXHL2500813HRS-2430注射液江苏恒瑞医药股份有限公司1CXHL2500810HRS-2430注射液江苏恒瑞医药股份有限公司1CXHL2500811SYH2061注射液石药集团中奇制药技术(石家庄)有限公司1CXHL2500812FNX020片成都凡诺西生物医药科技有限公司1CXHL2500805FNX020片成都凡诺西生物医药科技有限公司1CXHL2500804DM2080贴北京德默高科医药技术有限公司2.2CXHL2500807DM2080贴北京德默高科医药技术有限公司2.2CXHL2500808多替拉韦拉米夫定替诺福韦片上海迪赛诺医药集团股份有限公司2.3CXHL2500806苹果酸法米替尼胶囊江苏恒瑞医药股份有限公司2.4CXHL2500828羟乙磺酸达尔西利片江苏恒瑞医药股份有限公司2.4CXHL2500823羟乙磺酸达尔西利片江苏恒瑞医药股份有限公司2.4CXHL2500822瑞维鲁胺片江苏恒瑞医药股份有限公司2.4CXHL2500815注射用西罗莫司(白蛋白结合型)石药集团中奇制药技术(石家庄)有限公司2.4CXHL250080920价肺炎球菌多糖结合疫苗艾美探索者生命科学研发有限公司2.2CXSL2500667注射用SHR-1826苏州盛迪亚生物医药有限公司1CXSL2500689注射用SHR-A2009苏州盛迪亚生物医药有限公司1CXSL2500688注射用FH-006上海甫弘生物医药有限公司1CXSL2500687SHR-4610注射液上海盛迪医药有限公司1CXSL2500686注射用SHR-9839 (sc)苏州盛迪亚生物医药有限公司1CXSL2500685注射用SHR-A2102苏州盛迪亚生物医药有限公司1CXSL2500683注射用SHR-A2102苏州盛迪亚生物医药有限公司1CXSL2500682注射用BL-M24D1成都百利多特生物药业有限责任公司1CXSL2500680QX029N注射液江苏荃信生物医药股份有限公司1CXSL2500679IBI363信达生物制药(苏州)有限公司1CXSL2500672IBI363信达生物制药(苏州)有限公司1CXSL2500671SCTC21C注射液神州细胞工程有限公司1CXSL2500670GK01细胞注射液北京极客基因科技有限公司1CXSL2500669JH032注射液百泰生物药业有限公司1CXSL2500668SHR-1701注射液苏州盛迪亚生物医药有限公司1CXSL2500677SHR-7367注射液上海恒瑞医药有限公司1CXSL2500675注射用GenSci139长春金赛药业有限责任公司1CXSL2500673注射用HS-20093上海翰森生物医药科技有限公司1CXSL2500666异体自然杀伤(NK)细胞注射液苏州迈德通医药科技有限公司1CXSL2500665异体自然杀伤(NK)细胞注射液苏州迈德通医药科技有限公司1CXSL2500664异体自然杀伤(NK)细胞注射液苏州迈德通医药科技有限公司1CXSL2500663HM2002注射液上海环码生物医药有限公司1CXSL2500662注射用间充质干细胞(脐带)天津昂赛细胞基因工程有限公司1CXSL2500661IBI3026信达生物科技有限公司1CXSL2500660SYS6002石药集团巨石生物制药有限公司1CXSL2500654IBI3009信达生物制药(苏州)有限公司1CXSL2500657SYS6043石药集团巨石生物制药有限公司1CXSL2500656SYS6010石药集团巨石生物制药有限公司1CXSL2500658DP303c注射液石药集团巨石生物制药有限公司1CXSL2500655QLS2309注射液齐鲁制药有限公司1CXSL2500659注射用瑞康曲妥珠单抗苏州盛迪亚生物医药有限公司2.2CXSL2500684阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500681SHR-8068注射液苏州盛迪亚生物医药有限公司2.2CXSL2500678贝伐珠单抗注射液苏州盛迪亚生物医药有限公司2.2CXSL2500676阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500674 仿制药申请药品名称企业注册分类受理号格隆溴铵注射液河南普瑞药业有限公司3CYHS2502894格隆溴铵注射液河南普瑞药业有限公司3CYHS2502893艾拉戈克钠片南京正大天晴制药有限公司3CYHS2502892艾拉戈克钠片南京正大天晴制药有限公司3CYHS2502891盐酸纳洛酮注射液云南药科院生物医药股份有限公司3CYHS2502890氯化钾缓释片澳美制药(海南)有限公司3CYHS2502865西咪替丁片河北新石制药有限公司3CYHS2502862盐酸普萘洛尔片寿光富康制药有限公司3CYHS2502861吸入用盐酸丙卡特罗溶液成都康泰源医药科技有限责任公司3CYHS2502860吸入用盐酸丙卡特罗溶液成都康泰源医药科技有限责任公司3CYHS2502859醋酸葡萄糖维持液西安万隆制药股份有限公司3CYHS2502880注射用奈达铂吉斯美(武汉)制药有限公司3CYHS2502879复方匹可硫酸钠口服溶液湖南科伦制药有限公司3CYHS2502878注射用奈达铂吉斯美(武汉)制药有限公司3CYHS2502877法莫替丁片安若维他药业泰州有限公司3CYHS2502875阿仑膦酸钠口服溶液北京民康百草医药科技有限公司3CYHS2502869中性低钙腹膜透析液(碳酸氢盐-G1.5%)成都青山利康药业股份有限公司3CYHS2502887对乙酰氨基酚维生素C泡腾片新乡市常乐制药有限责任公司3CYHS2502868中性低钙腹膜透析液(碳酸氢盐-G1.5%)成都青山利康药业股份有限公司3CYHS2502886中性低钙腹膜透析液(碳酸氢盐-G1.5%)成都青山利康药业股份有限公司3CYHS2502885注射用氨苄西林钠/氯化钠注射液湖南科伦制药有限公司3CYHS2502884注射用氨苄西林钠/氯化钠注射液湖南科伦制药有限公司3CYHS2502883醋酸葡萄糖维持液西安万隆制药股份有限公司3CYHS2502881酮咯酸氨丁三醇片浙江华海制药科技有限公司3CYHS2502900氨溴特罗口服溶液千海始德堂(鹤壁)制药有限公司3CYHS2502856氢溴酸加兰他敏口服溶液(Ⅱ)湖北民康制药有限公司3CYHS2502854吡拉西坦注射液华中药业股份有限公司3CYHS2502825吡拉西坦注射液华中药业股份有限公司3CYHS2502824重酒石酸去甲肾上腺素注射液广东南国药业有限公司3CYHS2502844注射用盐酸多西环素江苏联环药业股份有限公司3CYHS2502839异丙托溴铵沙丁胺醇吸入喷雾剂南昌谷森生物制药有限公司3CYHS2502820盐酸溴己新口服溶液江西科为制药有限公司3CYHS2502813依巴斯汀口服溶液重庆希尔安药业有限公司3CYHS2502814盐酸肾上腺素注射液辰欣药业股份有限公司3CYHS2502823注射用硫酸多黏菌素B河北锐健医药科技有限公司3CYHS2502821聚普瑞锌颗粒福建海西新药创制股份有限公司3CYHS2502808倍他米松磷酸钠注射液安徽均大高科医药科技有限公司3CYHS2502807中性腹膜透析液(乳酸盐-G2.5%)石家庄四药有限公司3CYHS2502806中性低钙腹膜透析液(乳酸盐-G2.5%)石家庄四药有限公司3CYHS2502805硫酸镁注射液酒泉大得利制药股份有限公司3CYHS2502804法莫替丁注射液绪必迪药业(沧州)有限公司3CYHS2502800苯甲酸阿格列汀片石家庄四药有限公司4CYHS2502905来特莫韦注射液浙江海正药业股份有限公司4CYHS2502904复方氨基酸(15)双肽(2)注射液西安力邦制药有限公司4CYHS2502903苯磺酸左氨氯地平片辽宁康博士制药有限公司4CYHS2502902苯磺酸左氨氯地平片辽宁康博士制药有限公司4CYHS2502901注射用头孢他啶阿维巴坦钠浙江普洛巨泰药业有限公司4CYHS2502899乙酰半胱氨酸注射液武汉先路医药科技股份有限公司4CYHS2502898乳果糖口服溶液浙江康恩贝制药股份有限公司4CYHS2502896乳果糖口服溶液浙江康恩贝制药股份有限公司4CYHS2502895非奈利酮片浙江贝得药业有限公司4CYHS2502889非奈利酮片浙江贝得药业有限公司4CYHS2502888美阿沙坦钾片江苏天士力帝益药业有限公司4CYHS2502864美阿沙坦钾片江苏天士力帝益药业有限公司4CYHS2502863替尔泊肽注射液礼来苏州制药有限公司4CYHS2502874磷酸奥司他韦胶囊海南赛科药业有限公司4CYHS2502873替尔泊肽注射液礼来苏州制药有限公司4CYHS2502872替尔泊肽注射液礼来苏州制药有限公司4CYHS2502871替尔泊肽注射液礼来苏州制药有限公司4CYHS2502870腹膜透析液(乳酸盐-G4.25%)辰欣药业股份有限公司4CYHS2502867注射用甲苯磺酸奥马环素湖南科伦制药有限公司4CYHS2502882氟马西尼注射液浙江华海药业股份有限公司4CYHS2502897左卡尼汀口服溶液烟台万润药业有限公司4CYHS2502857瑞维那新吸入溶液广东洛斯特制药有限公司4CYHS2502855他克莫司软膏山东辰欣佛都药业股份有限公司4CYHS2502853他克莫司软膏山东辰欣佛都药业股份有限公司4CYHS2502852注射用醋酸卡泊芬净浙江华海药业股份有限公司4CYHS2502866瑞舒伐他汀依折麦布片(Ⅰ)陕西白鹿制药股份有限公司4CYHS2502858脂肪乳(10%)/氨基酸(15)/葡萄糖(20%)注射液沈阳海思科制药有限公司4CYHS2502876莫匹罗星软膏上海理想制药有限公司4CYHS2502835莫匹罗星软膏上海理想制药有限公司4CYHS2502834褪黑素颗粒宿州亿帆药业有限公司4CYHS2502833雌二醇片/雌二醇地屈孕酮片复合包装华润紫竹药业有限公司4CYHS2502832雌二醇片/雌二醇地屈孕酮片复合包装华润紫竹药业有限公司4CYHS2502831舒更葡糖钠注射液石药集团欧意药业有限公司4CYHS2502830注射用头孢哌酮钠舒巴坦钠/氯化钠注射液湖南科伦制药有限公司4CYHS2502829注射用头孢哌酮钠舒巴坦钠/氯化钠注射液湖南科伦制药有限公司4CYHS2502828沙库巴曲缬沙坦钠片北京双鹭药业股份有限公司4CYHS2502827沙库巴曲缬沙坦钠片北京双鹭药业股份有限公司4CYHS2502826丁二磺酸腺苷蛋氨酸肠溶片成都赛璟生物医药科技有限公司4CYHS2502845达格列净二甲双胍缓释片(IV)上海现代制药股份有限公司4CYHS2502843达格列净二甲双胍缓释片(I)上海现代制药股份有限公司4CYHS2502842乙酰半胱氨酸注射液浙江恒研医药科技有限公司4CYHS2502841盐酸乐卡地平片福建省宝诺医药研发有限公司4CYHS2502840达格列净二甲双胍缓释片(Ⅰ)浙江普洛康裕制药有限公司4CYHS2502838头孢托仑匹酯颗粒沐源(安徽)药业有限公司4CYHS2502837头孢托仑匹酯颗粒沐源(安徽)药业有限公司4CYHS2502836阿达帕林凝胶广州乐宓医药科技有限公司4CYHS2502851苯磺酸美洛加巴林片华北制药股份有限公司4CYHS2502850富马酸伏诺拉生片湖南迪诺制药股份有限公司4CYHS2502849罗沙司他胶囊杭州仟源保灵药业有限公司4CYHS2502848罗沙司他胶囊杭州仟源保灵药业有限公司4CYHS2502847盐酸罗哌卡因注射液峨眉山通惠制药有限公司4CYHS2502846非奈利酮片山东百诺医药股份有限公司4CYHS2502822双氯芬酸钠缓释片湖南九典制药股份有限公司4CYHS2502819羟考酮纳洛酮缓释片甘肃农垦药物碱厂有限公司4CYHS2502818左乙拉西坦片山东普瑞曼药业有限公司4CYHS2502815左乙拉西坦片山东普瑞曼药业有限公司4CYHS2502816左乙拉西坦片山东普瑞曼药业有限公司4CYHS2502817精氨酸布洛芬颗粒海南赛立克药业有限公司4CYHS2502812注射用硫酸艾沙康唑湖南华纳大药厂股份有限公司4CYHS2502811氧长春巨洋气体有限责任公司4CYHS2502810盐酸二甲双胍缓释片白云山东泰商丘药业有限公司4CYHS2502809阿托伐他汀钙片宁波大红鹰药业股份有限公司4CYHS2502803阿托伐他汀钙片宁波大红鹰药业股份有限公司4CYHS2502802碘普罗胺注射液鲁南贝特制药有限公司4CYHS2502801硫酸氨基葡萄糖胶囊郑州韩都药业集团有限公司4CYHS2502799西妥昔单抗注射液广东安普泽生物医药股份有限公司3.3CXSS2500081破伤风人免疫球蛋白广东丹霞生物制药有限公司3.4CXSS2500078注射用多黏菌素E甲磺酸钠南京正科医药股份有限公司3CYHL2500139普瑞巴林缓释片宜昌人福药业有限责任公司3CYHL2500138普瑞巴林缓释片宜昌人福药业有限责任公司3CYHL2500137精蛋白人胰岛素混合注射液(30R)恒敬合创生物医药(浙江)有限公司3.3CXSL2500653 进口申请药品名称企业注册分类受理号泊沙康唑口服混悬液Hetero Labs Limited5.2JYHS2500039司来帕格片MSN LABORATORIES PRIVATE LIMITED5.2JYHS2500038司来帕格片MSN LABORATORIES PRIVATE LIMITED5.2JYHS2500037司来帕格片MSN LABORATORIES PRIVATE LIMITED5.2JYHS2500036司来帕格片MSN LABORATORIES PRIVATE LIMITED5.2JYHS2500035MK-1084片Merck Sharp & Dohme LLC1JXHL2500210MK-1084片Merck Sharp & Dohme LLC1JXHL2500209MK-4280A注射液Merck Sharp & Dohme LLC1JXSL2500143ALXN1920注射液Alexion Pharmaceuticals, Inc.1JXSL2500142BAY 3401016 注射液Bayer AG1JXSL2500141AZD0486AstraZeneca AB1JXSL2500139AZD0486AstraZeneca AB1JXSL2500138Lebrikizumab注射液Eli Lilly and Company2.2JXSL2500140 中药相关申请药品名称企业注册分类受理号川芎定痛颗粒北京阳光合和中医药科技开发有限公司1.1CXZL2500064黄葶肺心平颗粒重庆希尔安药业有限公司1.1CXZL2500063杜仲木脂素胶囊江西普正制药股份有限公司1.2CXZL2500061杜仲木脂素提取物江西普正制药股份有限公司1.2CXZL2500060小儿肺热咳喘口服液黑龙江葵花药业股份有限公司2.3CXZL2500062清肺汤颗粒江西药都樟树制药有限公司3.1CXZS2500032颈舒颗粒黄山精制药业有限公司4CYZS2500008 注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市临床申请

2025-07-29

·Business Wire

Aptar’s First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon’s Otrivin ® Brand

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging. Aptar Pharma announces that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally Reinforcing circularity in pharmaceutical packaging Aptar Pharma’s Freepod® spray pump used with Haleon’s Otrivin® Nasal Spray is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for the full nasal spray device. ISCC PLUS certified manufacturing and supply chain Aptar Pharma is committed to helping its customers meet their sustainability goals, such as reducing the use of fossil-based materials in packaging. The Freepod® nasal spray components are made from bio-based resins derived from renewable feedstocks like bio-waste and residual oils, using an ISCC PLUS-certified mass balance approach. The Aptar Pharma manufacturing site in Mezzovico, Switzerland, is ISCC PLUS certified, ensuring full traceability of materials throughout the manufacturing process and supply chain. ISCC Plus certification also covers all external suppliers - including injection molding providers, service partners, and warehouses - guaranteeing a fully (ISCC) certified supply chain for the Freepod® components. Partnership for a more sustainable approach The joint sustainability approach between Haleon (formerly GSK Consumer Healthcare) and Aptar Pharma is built on a long-term partnership spanning over 30 years. This collaboration has led to significant achievements, including the Otrivin® Freepod® winning the World Packaging Award in 2019 for its innovative and sustainable design. The use of bio-based or renewable feedstocks for the Otrivin® products with Freepod® technology supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025** and by a third by 2030, compared to 2022 levels. Aptar Pharma’s Freepod® for Otrivin®, available globally, demonstrates Aptar’s commitment to sustainability and innovation. Looking ahead, this collaboration is anticipated to extend to Otrivin Nasal Mist, Haleon’s latest microdroplet technology, which is being rolled out globally since 2023. “At Aptar, sustainability is not just a responsibility - it’s a strategic advantage,” commented Gael Touya, President of Aptar Pharma. “The launch of Freepod® Futurity™ reflects our commitment to developing solutions that respond to consumers’ increasing demand for more sustainable healthcare delivery technologies. As a trusted partner to Haleon, we are proud to help drive the success of the Otrivin® brand while enabling a shift away from fossil-based materials in primary packaging. Supporting our partners in reaching their environmental goals reinforces our vision of supporting the healthcare industry, from Formulation to patient.” With a strong commitment to sustainability, Aptar Pharma continuously strives to reduce its environmental impact and support its partners in achieving their sustainability goals. *ISCC Plus certified bio-based feedstock, mass balance approach. **The end point for the goal delivery period is the end of the 2025 calendar year. About Aptar Pharma Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com. About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

2025-07-29

·药筛

广东联盟集采报量：单品最高49亿元，最低18万

我根据广东22省联盟双氯芬酸钠等品种续约报量数据，统计出每个产品+合并归类剂型的报量总数，乘以非独家P1价格（血液制品用P2价格），计算出产品的采购金额。人血白蛋白和氯化钠注射剂断层式领先，人血白蛋白注射剂接近50亿元排第一，氯化钠注射剂40多亿元排第二；不过这个金额和全国市场的整体销售金额相比，还有很大差距，是因为报量不足的原因，还是计算的价格原因呢？第三名的免疫球蛋白注射剂15亿元；碳酸钙D3竟然还有11亿，是我预料之外的；利妥昔单抗有11亿，上一轮信达独家中选，这轮有几个新上市企业，值得重点关注。金额最少的倍氯米松软膏剂仅有18万元，其次是托烷司琼口服溶液剂23万元。这类品种，集采有何意义？以下是完整名单：（摩熵药筛小程序高级会员用户，可以联系客服，获取更多原始分析数据）摩熵药筛小程序高级会员用户，可以联系客服，获取原始分析数据。用摩熵药筛小程序，查询产品集采中选信息！11批国采交流群已建，加客服微信，入群交流！

带量采购

100 项与双氯芬酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00904	双氯芬酸钠	M02AA15 D11AX18 M01AB05	DB00586

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
滑囊炎	日本	Hisamitsu Pharmaceutical Co., Inc.	2022-06-20
颈臂综合征	日本	Hisamitsu Pharmaceutical Co., Inc.	2022-06-20
腰痛	日本	Hisamitsu Pharmaceutical Co., Inc.	2022-06-20
癌症疼痛	日本	Hisamitsu Pharmaceutical Co., Inc.	2021-03-23
膝关节炎	美国	Horizon Therapeutics Ireland DAC	2014-01-16
骨关节炎	日本	Dojin Iyaku-Kako Co., Ltd.	2004-02-27
肩周炎	日本	Dojin Iyaku-Kako Co., Ltd.	2004-02-27
肌腱病	日本	Dojin Iyaku-Kako Co., Ltd.	2004-02-27
腱鞘炎	日本	Dojin Iyaku-Kako Co., Ltd.	2004-02-27
光化性角化病	美国	Fougera Pharmaceuticals, Inc.	2000-10-16
超敏反应	美国	Fougera Pharmaceuticals, Inc.	2000-10-16
怀孕	美国	Fougera Pharmaceuticals, Inc.	2000-10-16
可见病灶	美国	Fougera Pharmaceuticals, Inc.	2000-10-16
术后炎症	日本	Wakamoto Pharmaceutical Co., Ltd.	1989-03-31
强直性脊柱炎	美国	Novartis Pharmaceuticals Corp.	1988-07-28
类风湿关节炎	美国	Novartis Pharmaceuticals Corp.	1988-07-28
炎症	日本	Fujisawa Pharmaceutical Co., Ltd.	1973-08-08
疼痛	日本	Fujisawa Pharmaceutical Co., Ltd.	1973-08-08

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌痛	临床3期	美国	Novartis AG	2014-10-01
挫伤	临床3期	德国	Novartis AG	2011-01-01
四肢损伤	临床3期	德国	Novartis AG	2011-01-01
软组织损伤	临床3期	德国	Novartis AG	2011-01-01
踝损伤	临床3期	美国	Novartis AG	2010-11-01
晒伤	临床3期	法国	Novartis AG	2006-11-01
膝关节原发性骨关节炎 NOS	临床3期	美国	Nuvo Pharmaceuticals, Inc.	2004-02-01
意外伤害	临床1期	中国	四川天德制药有限公司	2022-10-14
痛风性关节炎	临床1期	中国	四川天德制药有限公司	2022-10-14
发热	临床1期	中国	四川天德制药有限公司	2022-10-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05947461 (DIPPP, Pubmed \| Gut)	N/A	ERCP术后胰腺炎	1,204	Rectal Diclofenac 100 mg	製餘夢鬱夢鹹遞築選糧(鏇遞憲範蓋顧襯齋衊築) = 餘獵窪遞遞夢窪繭襯築鑰鬱遞糧鏇鬱獵淵築膚 (齋製壓淵獵壓鑰齋製獵 )	不佳	2025-07-01
				Rectal Indomethacin 100 mg	製餘夢鬱夢鹹遞築選糧(鏇遞憲範蓋顧襯齋衊築) = 鑰蓋簾選壓選構網遞觸鑰鬱遞糧鏇鬱獵淵築膚 (齋製壓淵獵壓鑰齋製獵 )
NCT05968482 (CTgov)	临床1期	-	74	Diclofenac Sodium Gel (AMZ001 Low Dose)	鬱簾蓋鬱製簾簾顧齋簾(選艱觸積網蓋鏇構壓築) = 襯襯膚糧餘築鏇膚襯選顧鹹製選衊壓選齋選蓋 (膚壓憲夢餘鬱廠顧憲製, 89.8) 更多	-	2025-04-09
				Diclofenac Sodium Gel (AMZ001 High Dose)	鬱簾蓋鬱製簾簾顧齋簾(選艱觸積網蓋鏇構壓築) = 艱衊糧壓蓋積製餘構選顧鹹製選衊壓選齋選蓋 (膚壓憲夢餘鬱廠顧憲製, 90.3) 更多
ASCO2024	N/A	癌症疼痛	437	Diclofenac sodium suppository	糧蓋鹹夢壓範遞範觸廠(蓋製鏇選願廠鏇觸顧廠) = 5 pts experienced any grade treatment emergent adverse events (TEAEs). All TEAEs were grade 1-2. TEAE leading to treatment discontinuation was occurred in one pt. 廠鬱壓醖積壓艱鬱憲選 (簾衊積壓醖鬱積蓋鏇淵 )	积极	2024-05-24
				Placebo
D-ToRCH (ESMO2023)	临床3期	-	264	Topical diclofenac	鏇觸積網範網艱憲願製(繭鏇蓋糧鹽鹹顧齋鹹網) = 簾鑰顧顧壓構憲範鹽鬱繭積獵窪淵積積積鬱餘 (繭選願窪壓艱築鏇憲繭 ) 更多	-	2023-10-21
				Placebo	鏇觸積網範網艱憲願製(繭鏇蓋糧鹽鹹顧齋鹹網) = 蓋夢願選鹹觸顧衊窪鹽繭積獵窪淵積積積鬱餘 (繭選願窪壓艱築鏇憲繭 ) 更多
NCT05829707 (NCT05829707, Pubmed)	临床4期	乳腺癌	120	Levobupivacaine wound infiltration	遞觸糧淵築襯製願餘蓋(鏇鏇艱夢簾壓繭築憲衊) = 廠網醖網夢窪鹹獵遞製構積壓範夢簾顧醖鬱餘 (鬱餘鑰衊淵齋襯齋築齋 ) 更多	积极	2023-08-23
				Diclofenac analgesia	遞觸糧淵築襯製願餘蓋(鏇鏇艱夢簾壓繭築憲衊) = 獵願鬱衊構襯廠襯願積構積壓範夢簾顧醖鬱餘 (鬱餘鑰衊淵齋襯齋築齋 ) 更多
NCT04683627 (Corporate Publications) 人工标引	临床3期	膝关节炎	370	HP-5000	願夢簾淵願窪夢醖廠網(鏇齋繭壓築鏇餘鹹膚艱) = The study did not meet its primary endpoint of statistically significant improvement in the osteoarthritis knee pain score (WOMAC) from baseline to week 12 構鹽鏇膚選構糧鬱醖襯 (淵餘憲簾鏇鹽遞顧獵衊 )	不佳	2022-10-28
				placebo
NCT03861611 (CTgov)	临床4期	急性腰痛	198	Educational Intervention+Ketorolac (Ketorolac + Educational Intervention)	襯膚願憲鏇衊膚膚簾齋(憲簾觸襯積齋繭廠鹹齋) = 淵願艱繭鬱製窪憲膚襯遞繭願顧顧餘淵糧淵糧 (範網窪鹹糧鏇廠範壓願, 8.8) 更多	-	2022-05-31
				Educational Intervention+Ibuprofen (Ibuprofen + Educational Intervention)	襯膚願憲鏇衊膚膚簾齋(憲簾觸襯積齋繭廠鹹齋) = 蓋願蓋製鑰餘糧餘積範遞繭願顧顧餘淵糧淵糧 (範網窪鹹糧鏇廠範壓願, 9.5) 更多
NCT03277066 (HP-5000, CTgov)	临床2期	膝关节炎	289	Placebo patch+Diclofenac Sodium Active Topical Patch 1 (Diclofenac Sodium Active Topical Patch 1)	獵鹽構繭鹽鏇艱壓餘壓(廠淵積遞築簾獵願壓範) = 夢鏇簾簾願簾窪願選膚願窪積夢齋鹹觸鹽艱構 (築夢糧顧積範衊積願淵, 4.47) 更多	-	2021-12-23
				Placebo patch+Diclofenac Sodium Active Topical Patch 2 (Diclofenac Sodium Active Topical Patch 2)	獵鹽構繭鹽鏇艱壓餘壓(廠淵積遞築簾獵願壓範) = 艱襯窪選憲構範壓製憲願窪積夢齋鹹觸鹽艱構 (築夢糧顧積範衊積願淵, 4.06) 更多
NCT00726388 (CTgov)	临床3期	术后疼痛	1,050	DIC075V	衊醖獵鹹鹽遞艱窪遞憲 = 遞淵獵獵遞獵壓築鬱憲艱憲顧簾夢鏇網製餘鏇 (鑰製鬱觸遞淵鹹膚鬱觸, 願壓鬱齋廠衊淵範糧觸 ~ 獵網製齋願餘衊積襯憲) 更多	-	2021-10-13
NCT04391842 (SAM, CTgov)	临床1期	膝关节炎	34	Sustained Acoustic Device with 1% Diclofenac patch	構壓顧製艱築積遞衊觸(齋構簾鑰鏇壓構夢選膚) = 鏇窪鏇鹽鏇壓鑰艱製築遞餘淵製鑰獵憲鑰網網 (鏇顧鑰餘衊顧鏇餘襯繭, 2.41) 更多	-	2021-09-23